Relmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in London
Relmada Therapeutics (Nasdaq: RLMD) will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 16, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Relmada Therapeutics (Nasdaq: RLMD) will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 16, 2026.
CEO Sergio Traversa and CFO Maged Shenouda will attend. The chat is scheduled for 12:00 PM GMT/7 AM ET, and management will be available for one-on-one investor meetings during the conference. A webcast replay will remain available for 90 days after the event.
Details
News Market Reaction – RLMD
On Nov 4, the day this news came out, RLMD closed 2.34% below the previous close. Our momentum scanner recorded 5 alerts for this stock that day. That session’s volume was 1.6x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Nov 4 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CORAL GABLES, Fla., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference being held in London, UK, from November 16 - 19, 2026.
Jefferies Global Healthcare Conference in London
Format: Fireside Chat
Date: Monday, November 16, 2026
Time: 12:00 PM GMT/7 AM ET
Webcast: Click Here
Management will also be available for one-on-one investor meetings during the conference. Please contact your Jefferies representative to schedule a meeting.
The webcast can also be accessed on the Events page of the Investors section of the Relmada website at https://ir.relmada.com/investors/events/. An archived replay will be available for 90 days following the conclusion of the event.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through clinical development with the potential to address significant unmet needs.
For more information, visit www.relmada.com
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
Media Inquiries:
Corporate Communications
media@relmada.com
